HUMA
Humacyte Inc
NASDAQ: HUMA · HEALTHCARE · BIOTECHNOLOGY
$0.84
+2.66% today
Updated 2026-04-30
Market cap
$178.93M
P/E ratio
—
P/S ratio
87.79x
EPS (TTM)
$-0.26
Dividend yield
—
52W range
$1 – $3
Volume
6.7M
Humacyte Inc (HUMA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-71.79M | $-55.57M | $-81.19M | $-71.13M | $-73.31M | $-98.12M | $-105.04M |
| Capital expenditures | $8.13M | $318000.00 | $220000.00 | $1.05M | $2.28M | $1.57M | $884000.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $4.46M | $4.69M | $10.15M | $6.18M | $6.83M | $6.14M | $9.75M |
| Free cash flow | $-79.91M | $-55.89M | $-81.41M | $-72.18M | $-75.58M | $-99.69M | $-105.93M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | $0.00 | $0.00 |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $177.57M | $-67.73M | — | — | — |